By Kulmeet Kundlas MD, Board-Certified Internal Medicine — Shield Medical Group, Sebring and Lake Wales, Florida. Schedule Urgent Care.
If you are over 50 and living with type 2 diabetes, you have heard the noise about the GLP-1 drugs. On August 28, 2026, the FDA changed the label for Mounjaro (tirzepatide), and it is worth your attention. The agency now says this medication does more than lower your A1C, help your blood pressure, and ease sleep apnea. It also lowers your risk of a future heart attack and stroke.
Most of us in primary care already suspected this. What changed on August 28 is that it is now official, printed on the package, and something I can tell you with confidence in the exam room. Let me explain what the studies actually found and where this drug fits for you.
Is Mounjaro Just a Cosmetic Weight-Loss Drug?
No. For a long time tirzepatide was used only for two jobs: bringing down A1C and taking off weight. As of August 28, the FDA has added a third, and it is the one that matters most for longevity — reducing the risk of heart attack and stroke.
For you, that means when we start this medication we are not just chasing better lab numbers. There is a real, measured layer of protection for your heart that comes with it.
What the SURPASS Cardiovascular Trial Showed
The study was set up in an honest way. We already had Trulicity (dulaglutide), a GLP-1 drug proven to cut the risk of heart attack and stroke. So the researchers did not test Mounjaro against a placebo. They tested it head-to-head against Trulicity.
It was a big trial: about 13,000 patients in more than 30 countries. And these were not lightly treated people. Their blood pressure medication, their cholesterol medication, their diet, their exercise, and their Trulicity were all maximized before Mounjaro entered the picture. Even against that bar, Mounjaro held its own and then edged slightly ahead on cardiovascular events.
The gap was about one percentage point. That sounds like nothing until you remember how many people take these drugs. Across a population, one point is a very large number of strokes and heart attacks that did not happen.
Why Would a Diabetes Drug Protect Your Heart?
Diabetes is an inflammatory disease, not just a sugar problem. I tell patients to picture high blood sugar as liquid sandpaper, quietly scraping the inside lining of the blood vessels day after day. That irritation drives the inflammation that leads to heart attacks and strokes.
Mounjaro works on two receptors at once, GLP-1 and GIP. That dual action seems to calm the inflammation more than a single-receptor drug, and in the trial that showed up as fewer cardiovascular events. It is not a guess. The researchers measured inflammatory markers, not just weight and glucose.
This is the direction all of diabetes care is moving, away from “get the A1C down” and toward “fix the metabolic disease.” The American Diabetes Association Standards of Care reflect that shift, and it is the same reason we now reach for SGLT2 inhibitors, which protect the kidneys and the heart and help keep patients out of heart failure.
Side Effects and Who Should Not Take It
None of this is free. The stomach and bowel side effects are what limit the drug for most people:
- Nausea is the common one, worst when you start or step up the dose, and it usually settles over a few weeks.
- Diarrhea or constipation happens in a smaller number of people and is generally mild.
- Pancreatitis is rare but real. Severe abdominal pain that will not let up needs to be checked right away.
- Medullary thyroid cancer or MEN 2 syndrome in you or your family is a reason not to use this class at all.
Outside of those situations, most people do well on it.
The Lifestyle Factor
Here is what worries me. I am watching people start one of these medications and then quietly ease off the walking, the lifting, and the cooking. When a pill starts doing the work, it is human nature to stop doing yours. Every physician I know has this same fear.
Remember how the heart benefit was found: in people who had already maxed out their treatment and their habits. The drug added to that. It did not replace it. If you skip your part, I do not think you get the full result. On any GLP-1 medication you need to:
- Do resistance exercise, so you keep the muscle you would otherwise lose along with the fat.
- Eat enough protein to protect that muscle.
- Stay active every day. A short walk after your biggest meal still helps your sugar and your heart.
You cannot take a molecule this strong and change nothing else.
The Bigger Picture
I believe these drugs get closer to the root of the problem than anything we have had. Trial after trial has shown the same thing: help a person with diabetes lose weight, and heart disease, stroke, liver disease, and overall mortality all move in the right direction. Mounjaro’s makers had to prove that to regulators before they could print it on the box. They did. For those of us treating patients, it is a confirmation of something we already believed.
Newer medicine keeps arriving. Our job is to stay healthy enough to take advantage of it when it does, and to keep holding up our end in the meantime.
Frequently Asked Questions
Does the FDA approval mean Mounjaro is now a heart medication?
It means Mounjaro is approved to reduce the risk of heart attack and stroke in adults with type 2 diabetes who have cardiovascular disease or risk factors, on top of its diabetes and weight uses. It does not replace your blood pressure, cholesterol, or blood-thinning medications.
How is Mounjaro different from Ozempic or Trulicity?
Trulicity (dulaglutide) and Ozempic (semaglutide) act on one receptor, GLP-1. Mounjaro (tirzepatide) acts on two, GLP-1 and GIP. That tends to produce more weight loss, and in the SURPASS cardiovascular trial it gave at least as much heart protection as Trulicity.
Will I still get the heart benefit if I don’t exercise or change my diet?
Probably not all of it. Everyone in the trial had already maximized diet, exercise, and their other medications. The heart protection was measured on top of that base, not instead of it.
Who should not take Mounjaro?
Anyone with a personal or family history of medullary thyroid cancer or MEN 2 syndrome. People with a history of pancreatitis should weigh it carefully with their doctor. Stop the medication if you are planning a pregnancy or become pregnant.
What are the most common side effects?
Nausea, especially early on or after a dose increase. Diarrhea and constipation are less common. Pancreatitis is rare.
The Bottom Line
If you are on Mounjaro, this is good news you can trust: it now has evidence behind it for protecting your heart, not only your blood sugar and your weight — as long as you keep doing the lifestyle work alongside it. Ask your primary care physician whether it fits your plan. If you do not have one, here is why that matters.
At Shield Medical Group in Sebring and Lake Wales, Florida, we manage GLP-1 therapy and heart risk together every day. To be seen, call (863) 236-9550 or book a same-day appointment.
Educational only; talk to your clinician about your own situation. This is Dr. Kundlas — like, share, and subscribe, and I will see you in the next video.
